8. CONFLICT OF INTEREST
All members of the EAU Non-neurogenic MLUTS Guidelines Panel have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is reported below and is also publicly accessible through the European Association of Urology website: http://uroweb.org/guidelines.
Disclosures: The EAU Guidelines Office certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following:
Jean-Nicolas Cornu certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g. employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received or pending), are the following:
M. Baboudjian reported serving as a company consultant to Coloplast; receiving company speaker honoraria from Ambu A/S and Accord Healthcare; and receiving honoraria or consultation fees from Rocamed and Boston Scientific. M. Creta reported participating in company-sponsored speaker’s training events with Medac Pharma S.r.l. J.-N. Cornu reported serving as a company consultant to STIMULI Technology (French), AbbVie, Boston Scientific, Coloplast, B. Braun Medical, Stimuli Technology, Medtronic France S.A.S. Stimuli Technology and Boston Scientific. C. De Nunzio reported receiving company speaker honoraria from Accord, Bayern Ferring, Janssen, Pierre fabre, Sanophy and Ipsen; receiving fellowship and travel grants from Ipsen, AB Medica, Biostylogit, Pierre fabre, Janssen, Idipharma; and participating in trials for Stimuli Technology, Janssen, Ipsen, Bayer, Teleflex and Pierre fabre. D. Elterman reported serving as a company consultant to Boston Scientific, Medi-Tate Ltd., Olympus Corporation, Procept Biorobotics, Zenflow, Inc., Urotronic, Medtronic Inc. and Laborie Medical Technologies Europe B.V; and receiving company speaker honoraria from Atellas Pharma. H. Hashim reported serving as a company consultant to Astellas, Boston Scientific, Medtronic and Tensi +; receiving company speaker honoraria from Astellas and Medtronic; serving as Co-Chair of the International Continence Society (ICS), and as Journal Associate Editor for Neurourology and Urodynamics and BJUI Compass; and participating in clinical trials with Astellas, Medtronic, and Boston. T.R.W. Herrmann reported serving as a company consultant to Karl Storz SE & Co. KG. S. Malde reported receiving honoraria or consultation fees from Medtronic. C. Netsch reported serving as a company consultant to Lisa Laser, Olympus, KLS-Martin, Biolitec, and Richard Wolf GmbH; receiving company speaker honoraria from Richard Wolf GmbH and Richard Wolf; and receiving honoraria or consultation fees from Boston Scientific. M. Rieken reported serving as company consultant to Schwabe Pharma and received speaker honoraria from Astellas Pharma, Boston Scientific and Schwabe Pharma. V. Sakalis reported serving as a company consultant to Ipsen Epe; receiving fellowship or travel grants from Anastasios Mavrogenis S.A. and Ariti S.A.; and receiving grants or research support from Demo Pharmaceutical Industry. M. Tutolo reported receiving company speaker honoraria from Pierre Fabre. M. Karavitakis, M.B. Duran, L. Moris, and N. Pyrgidis have nothing to declare.
This Guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation, and funding is limited to administrative and travel and meeting expenses. No honoraria or other reimbursements have been provided.